Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
JCO Oncology Practice|March 3, 2022
Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine ChemotherapyKyoin Koo, Amy L Pasternak, N Lynn Henry, et al.
Pharmacogenetics and Genomics|September 3, 2025
Association of genetic variation with irinotecan infusion reactions and severe toxicityKelly I Nugent, Lyucheng Huang, Maisa Nazzal, et al.
Clinical Pharmacology and Therapeutics|December 7, 2023
Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant AllelesJavier Granados, Amy L Pasternak, N Lynn Henry, et al.
Physiological Genomics|September 10, 2017
Germline genetic variants with implications for disease risk and therapeutic outcomesAmy L Pasternak, Kristen M Ward, Jasmine A Luzum, et al.
Pharmacogenetics and Genomics|October 29, 2024
CYP3A5 pharmacogenetic testing for tacrolimus in pediatric heart transplant patients: a budget impact analysisJiaqi Wang, Amy L Pasternak, Simran Maggo, et al.
Cleveland Clinic Journal of Medicine|February 5, 2020
Pharmacogenomics: An evolving clinical tool for precision medicineJennifer K Hockings, Amy L Pasternak, Angelika L Erwin, et al.
Pharmacogenomics and Personalized Medicine|March 22, 2021
Evaluating the Impact of CYP3A5 Genotype on Post-Transplant Healthcare Resource Utilization in Pediatric Renal and Heart Transplant Recipients Receiving TacrolimusAmy L Pasternak, Vincent D Marshall, Christina L Gersch, et al.
Pharmacogenomics|October 6, 2021
SLCO1B3 polymorphisms and clinical outcomes in kidney transplant recipients receiving mycophenolateLauren Schumacher, Fang Fang, Kelley M Kidwell, et al.
Pharmacogenetics and Genomics|February 7, 2026
The role of uridine diphosphate glucuronosyltransferase 1A4 polymorphisms on posaconazole exposureKatherine Zhao, Vy Lam, Gregory Eschenauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2026
Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variantsNam Nguyen-Hoang, Kelly Nugent, Sophia Jaso, et al.
Pageof 4